Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: Innovators, biosimilars, and intended copies

Joint Bone Spine

Volumn 81, Issue 6, 2014, Pages 471-477

  Castañeda Hernández, Gilberto ^a   Szekanecz, Zoltan ^b   Mysler, Eduardo ^c   Azevedo, Valderilio F ^d   Guzman, Renato ^e   Gutierrez, Miguel ^f   Rodríguez, Wilfredo ^g   Karateev, Dmitry ^h  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c Organización Médica de Investigación ^*  (Argentina)

^d FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^e Chief of ImmunoRheumatology Saludcoop Clinic and Scientific Director of IDEARG   (Colombia)

^f PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^g HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^h INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Biopharmaceuticals; Biosimilars; Innovators; Rheumatic diseases; Rheumatoid arthritis; Tumor necrosis factor (TNF) antagonists

Indexed keywords

ADALIMUMAB; BIOSIMILAR AGENT; ETANERCEPT; INFLIXIMAB; INNOVATOR AGENT; INTENDED COPY; MONOCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; GENERIC DRUG;

BIOEQUIVALENCE; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPEAN MEDICINES AGENCY; HUMAN; IMMUNOGENICITY; PATENT; POSTMARKETING SURVEILLANCE; REVIEW; RHEUMATOID ARTHRITIS; EUROPE; INDIA; PHARMACEUTICS; RHEUMATIC DISEASES; RUSSIAN FEDERATION; SOUTH AND CENTRAL AMERICA;

BIOPHARMACEUTICS; BIOSIMILAR PHARMACEUTICALS; DRUGS, GENERIC; EUROPE; HUMANS; INDIA; LATIN AMERICA; RHEUMATIC DISEASES; RUSSIA;

EID: 84922611724     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.03.019     Document Type: Short Survey

References (43)

1. Ebbers H.C., Crow S.A., Vulto A.G., et al. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012, 30:1186-1190.
2. Dorner T., Strand V., Castaneda-Hernandez G., et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013, 72:322-328.
3. Lapadula G., Ferracioli G.G. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin Exp Rheumatol 2012, 30:s102-s106.
4. Strober B.E., Armour K., Romiti R., et al. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol 2012, 66:317-322.
5. Laki J., Székelyné Monók G. Biológiai terápia 2006-2010 Elemzés. Országos Egészségbiztosítási Pénztár 2012, Available from: http://www.oep.hu/pls/portal/docs/PAGE/SZAKMA/OEPHUSZAK_EUSZOLG/TIBI%20EGY%C3%89B/SZAKMAI%20ELLEN%C5%90RZ%C3%89S/BIOL_TH_2006_2010_PUBLIKUS4.PDF (accessed May 2013).
6. Szekanecz Z. [Biosimilar drugs in rheumatology-the clinician's dilemma]. OrvostovábbképzÔ Szemle 2013, 1-7.
7. Mc Camish M., Woollett G. The state of the art in the development of biosimilars. Clin Pharm Ther 2012, 91:405-417.
8. Mullard A. Can next-generation antibodies offset biosimilar competition?. Nature Rev Drug Discov 2012, 11:426-428.
9. Dranitsaris G., Amir E., Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs 2011, 71:1527-1536.
10. Kay J., Smolen J. Biosimiliars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013, 72:1589-1593.
11. Department of Health US Human Services, Food and Drug Administration, Center for Drug Evaluation Research (CDER), et al. Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product (draft) 2012, Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf (accessed May 2013).
12. Department of Health US Human Services, Food and Drug Administration, Center for Drug Evaluation Research (CDER), et al. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product (draft) 2012, Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (accessed May 2013).
13. Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther 2011, 13:112.
14. Scheinberg M.A., Azevedo V.F. Biosimiliars in rheumatology: perspective and concerns. Rheumatology 2013, doi: 10/1093/rheumatology/ket210 [Epub ahead of print].
15. Kozlowski S., Woodcock J., Midthun K., et al. Developing the nation's biosimilars program. N Engl J Med 2011, 365:385-388.
16. World Health Organization (WHO) Guidelines on evaluation of similar biotherapeutic products (SBPs) 2009, Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf (accessed May 2013).
17. Azevedo V.F., Sandorff E., Siemak B., et al. Potential regulatory and commercial environment for biosimilars in Latin America. Value Health Regional Issues 2012, 1:228-234.
18. Scheinberg M.A., Kay J. The advent of biosimilar therapies in rheumatology-"O brave new world". Nat Rev Rheumatol 2012, 8:430-436.
19. Subramanyam M. Clinical development of biosimilars: an evolving landscape. Bioanalysis 2013, 5:575-586.
20. Elewaut D., Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford) 2009, 48:1029-1035.
21. Calvo B., Zuniga L. The US approach to biosimilars: the long-awaited FDA approval pathway. BioDrugs 2012, 26:357-361.
22. Weise M., Bielsky M.C., De Smet K., et al. Biosimilars: what clinicians should know. Blood 2012, 120:5111-5117.
23. Wang Y.M., Chow A.T. Development of biosimilars-pharmacokinetic and pharmacodynamic considerations. J Biopharm Stat 2010, 20:46-61.
24. Kessler M., Goldsmith D., Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006, 21:v9-v12.
25. Korswagen L.A., Bartelds G.M., Krieckaert C.L., et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 2011, 63:877-883.
26. Wolbink G.J., Vis M., Lems W., et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:711-715.
27. Ducourau E., Mulleman D., Paintaud G., et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011, 13:R105.
28. Looney R.J., Anolik J.H., Campbell D., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50:2580-2589.
29. Levi M., Grange S., Frey N. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis. J Clin Pharmacol 2012, 53:151-159.
30. Kuhlmann M., Marre M. Lessons learned from biosimilar epoetins and insulins. Br J Diabetes Vasc Dis 2010, 10:90-97.
31. European Medicines Agency Guideline on similar biological medicinal products (draft) 2013, Available from: http://ww.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500142978.pdf (accessed May 2013).
32. FirstWord Pharma ViewPoints: Novartis' Sandoz unit moves biosimilar Enbrel into Phase III testing-extrapolation issues highlighted once again 2013, Available from: http://www.firstwordpharma.com/node/1087000 (accessed June 2013).
33. Mysler E., Scheinberg M. Biosimilars in rheumatology: a view from Latin America. Clin Rheumatol 2012, 31:1279-1280.
34. Malhotra H. Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation. Biologicals 2011, 39:321-324.
35. Government of India Guidelines on similar biologics: regulatory requirements for marketing authorization in India 2012, Available from: http://dbtbiosafety.nic.in/Files%5CCDSCO-DBTSimilarBiologicsfinal.pdf (accessed May 2013).
36. Burgos-Vargas R., Catoggio L.J., Galarza-Maldonado C., et al. Current therapies in rheumatoid arthritis: a Latin American perspective. Reumatol Clin 2013, 9:106-112.
37. Rondon F., Bautista A., Salazar J.C., et al. Etanar therapy in real-life patients with rheumatoid arthritis. Arthritis Rheum 2010, 62:1811.
38. Comisión Federal para la Protección contra Riesgos Sanitarios Comunicado a los profesionales de la salud sobre Rituximab 4 de abril de 2012 2012, Available from: http://www.cofepris.gob.mx/AZ/Paginas/Farmacovigilancia/Comunicados.aspx (accessed August 2013).
39. Rivera V.M. The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology 2010, 74:864.
40. Reingold S.C., Steiner J.P., Polman C.H., et al. The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology 2009, 73:552-559.
41. Gu N., Yi S., Kim T.E., et al. Comparative pharmacokinetics and tolerability of branded etanercept (25mg) and its biosimilar (25mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. Clin Ther 2011, 33:2029-2037.
42. Yoo D.H., Hrycaj P., Miranda P., et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013, 72:1613-1620.
43. Park W., Hrycaj P., Jeka S., et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013, 72:1605-1612.